2013
Phenotypic properties of transmitted founder HIV-1
Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP, Bjorkman PJ, Wilen CB, Doms RW, O’Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH. Phenotypic properties of transmitted founder HIV-1. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 6626-6633. PMID: 23542380, PMCID: PMC3637789, DOI: 10.1073/pnas.1304288110.Peer-Reviewed Original ResearchConceptsChemokine receptor 5TF virusesSubtype BT cellsFounder HIV-1Respective patient cohortsHIV-1 transmissionHIV-1 infectionDendritic cell interactionsT-cell tropismAIDS vaccine developmentPresence of IFNDe novo infectionIFN-α resistanceInfectious molecular cloneAIDS vaccinePatient cohortCell-free infectivityPrimary CD4HIV-1Env contentReceptor 5Virus-host interactionsNovo infectionVaccine development
2011
Phenotypic and Immunologic Comparison of Clade B Transmitted/Founder and Chronic HIV-1 Envelope Glycoproteins
Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW. Phenotypic and Immunologic Comparison of Clade B Transmitted/Founder and Chronic HIV-1 Envelope Glycoproteins. Journal Of Virology 2011, 85: 8514-8527. PMID: 21715507, PMCID: PMC3165820, DOI: 10.1128/jvi.00736-11.Peer-Reviewed Original ResearchConceptsMucosal barrierF EnvsNeutralization sensitivitySingle-round infectivity assaysHuman immunodeficiency virus type 1Immunodeficiency virus type 1Enhanced neutralization sensitivityTransmitted/FounderHIV-1 envelope glycoproteinHIV-1 transmissionIntact mucosal barrierClade B EnvVirus type 1Chronic EnvsHIV-IgDendritic cellsCoreceptor tropismFounder virusesSexual transmissionEnv phenotypeAntibody b12Chronic controlEffective vaccineNew infectionsEnv trimers